Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immunotherapy combo may save bladders in cancer patients

NCT ID NCT06237920

Recruiting now Disease control Sponsor: The Netherlands Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests two immunotherapy drugs, nivolumab and relatlimab, given before surgery for stage II-IIIa bladder cancer. The goal is to see if the combination can eliminate the tumor, allowing patients to keep their bladder instead of having it removed. About 90 participants will receive either nivolumab alone or with relatlimab, and doctors will check for complete response after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

nivolumab (Opdivo) and relatlimab (BMS-986016)

What this could lead to

If successful, this could offer a way to treat bladder cancer without removing the bladder, preserving quality of life.

What could go wrong

This is an early phase 2 trial with only 90 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation of organs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign urinary system neoplasm chemotherapy-induced toxicity Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications infiltrating bladder urothelial carcinoma Male Urogenital Diseases neoplasm Neoplasms by Site urinary bladder disorder urinary bladder neoplasm Urinary Bladder Neoplasms urinary system neoplasm Urogenital Diseases Urogenital Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTINEOPLASTICS TOXICITY FEMALE UROGENITAL DISEASES FEMALE UROGENITAL DISEASES AND PREGNANCY COMPLICATIONS MALE UROGENITAL DISEASES NEOPLASMS NEOPLASMS BY SITE URINARY BLADDER DISEASES URINARY BLADDER NEOPLASM UROGENITAL DISEASES UROGENITAL NEOPLASMS UROLOGIC NEOPLASMS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Amsterdam UMC (AUMC)

    RECRUITING

    Amsterdam, North Holland, 1081HV, Netherlands

    Contact

  • Erasmus Medical Center

    RECRUITING

    Rotterdam, Zuid_Holland, 3015GD, Netherlands

    Contact

  • ISALA

    NOT_YET_RECRUITING

    Zwolle, Overijssel, 8025AB, Netherlands

    Contact

  • Leiden University Medical Center (LUMC)

    RECRUITING

    Leiden, South Holland, 2333ZA, Netherlands

    Contact

  • NKI-AVL

    RECRUITING

    Amsterdam, North Holland, 1066CX, Netherlands

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Radboud University Medical Center

    RECRUITING

    Nijmegen, Gelderland, 6525GA, Netherlands

    Contact

  • Rijnstate

    NOT_YET_RECRUITING

    Arnhem, Gelderland, 6815AD, Netherlands

    Contact

  • Spaarne Gasthuis

    RECRUITING

    Hoofddorp, North Holland, 2143TM, Netherlands

    Contact

  • University Medical Center Utrecht

    RECRUITING

    Utrecht, 3584CX, Netherlands

    Contact